Bioethics and Post-approval Research in Translational Science

REFERENCES

• Berlin , J. A. , Glasser , S. C. and Ellenberg , S. S. 2008 . Adverse event detection in drug development: Recommendations and obligations beyond phase 3 . American Journal of Public Health , 98 ( 8 ) : 1366 – 1371 .
   PubMed Web of Science ®Google Scholar
• Dawson , L. , Zarin , D. , Emanuel , E. , Freidman , L. , Chaudhari , B. and Goodman , S. 2009 . Considering usual medical care in clinical trial design . PLoS Medicine , 6 ( 9 ) : e1000111
   Web of Science ®Google Scholar
• Glasser , S. P. , Salas , M. and Delzell , E. 2007 . Importance and challenges of studying marketed drugs: What is a phase IV study? Common clinical research designs, registries, and self-reporting systems . Journal of Clinical Pharmacology , 47 : 1074 – 1086 .
   PubMed Web of Science ®Google Scholar
• Moynihan , R. 2010 . Rosiglitazone, marketing, and medical science . British Medical Journal , 340 : 785 – 789 .
   Google Scholar
• Nissen , S. E. 2010 . The rise and fall of rosiglitazone . European Heart Journal , 31 : 773 – 776 .
   PubMed Web of Science ®Google Scholar
• Nissen , S. E. and Wolski , K. 2007 . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes . New England Journal of Medicine , 356 ( 24 ) : 2457 – 2471 .
   PubMed Web of Science ®Google Scholar
• Sofaer , N. and Eyal , N. 2010 . The diverse ethics of translational research . American Journal of Bioethics , 10 ( 8 ) : 19 – 30 .
   PubMed Web of Science ®Google Scholar
• Strom , B. L. 2006 . How the US drug safety system should be changed . Journal of the American Medical Association , 295 ( 17 ) : 2072 – 2075 .
   Web of Science ®Google Scholar